A phase I/II clinical trial, KEYNOTE-022, demonstrated that in melanoma patients with poor prognostic factors, the mPFS was 16.0 months in the BRAF-MEK inhibitor (dabrafenib and trametinib) and pembrolizumab group versus 10.3 months in dabrafenib and trametinib group [94]. This evidence concerns the gene MAP2K7 and melanoma.